212 related articles for article (PubMed ID: 30936376)
1. Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.
Quach HT; Robbins CJ; Balko JM; Chiu CY; Miller S; Wilson MR; Nelson GE; Johnson DB
Oncologist; 2019 Jul; 24(7):872-876. PubMed ID: 30936376
[TBL] [Abstract][Full Text] [Related]
2. Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab.
Shah N; Jacob J; Househ Z; Shiner E; Baird L; Soudy H
J Immunother Cancer; 2019 Sep; 7(1):247. PubMed ID: 31511075
[TBL] [Abstract][Full Text] [Related]
3. A case of childhood Brucellosis with neurological involvement and epididymo-orchitis.
Kanık-Yüksek S; Gülhan B; Ozkaya-Parlakay A; Tezer H
J Infect Dev Ctries; 2014 Dec; 8(12):1636-8. PubMed ID: 25500664
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
5. Tuberculous epididymo-orchitis mimicking a testicular tumour: a case report.
Badmos KB
Afr Health Sci; 2012 Sep; 12(3):395-7. PubMed ID: 23382759
[TBL] [Abstract][Full Text] [Related]
6. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter 2 inhibitor-associated severe epididymo-orchitis.
Mishra R; Elshimy G; Kannan L; Raj R
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35817490
[TBL] [Abstract][Full Text] [Related]
8. Brucellar epididymo-orchitis in Saudi Arabia: a retrospective study of 26 cases and review of the literature.
Memish ZA; Venkatesh S
BJU Int; 2001 Jul; 88(1):72-6. PubMed ID: 11446850
[TBL] [Abstract][Full Text] [Related]
9. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
10. Isolated tuberculous epididymo-orchitis: an unusual presentation of tuberculosis.
Shenoy VP; Viswanath S; D'Souza A; Bairy I; Thomas J
J Infect Dev Ctries; 2012 Jan; 6(1):92-4. PubMed ID: 22240436
[TBL] [Abstract][Full Text] [Related]
11. Tubercular epididymo-orchitis masquerading as testicular malignancy: an interesting case.
Sachdev R; Roy S; Jain S
Acta Cytol; 2008; 52(4):511-2. PubMed ID: 18702376
[No Abstract] [Full Text] [Related]
12. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
13. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
Thomas M; Armenti ST; Ayres MB; Demirci H
JAMA Ophthalmol; 2018 May; 136(5):553-556. PubMed ID: 29677240
[TBL] [Abstract][Full Text] [Related]
14. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
15. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
16. Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy.
Menke JJ; Heins JR
Ann Pharmacother; 2000 Apr; 34(4):479-82. PubMed ID: 10772435
[TBL] [Abstract][Full Text] [Related]
17. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
[TBL] [Abstract][Full Text] [Related]
18. Crimean-Congo haemorrhagic fever presenting as epididymo-orchitis.
Aksoy HZ; Yilmaz G; Aksoy F; Koksal I
J Clin Virol; 2010 Aug; 48(4):282-4. PubMed ID: 20598630
[TBL] [Abstract][Full Text] [Related]
19. Brucella epididymo-orchitis: a consideration in endemic area.
Al-Tawfiq JA
Int Braz J Urol; 2006; 32(3):313-5. PubMed ID: 16813677
[TBL] [Abstract][Full Text] [Related]
20. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
